The chromosomal translocation specifically linked to the Ewing sarcoma family results in the generation of fusion proteins comprising the amino terminal portion of EWS and the DNA-binding domain of ets transcription factors. The EWS/ets chimeric proteins act as aberrant transcription factors leading to tumorigenic processes. We searched for genes specifically activated in Ewing sarcoma cells but not in other tumor cell lines using the gene array technique, and found significantly enhanced expression of the Id2 gene. High levels of Id2 transcripts were detected in Ewing sarcoma cell lines and tumor tissues. The EWS/ ets chimeric proteins activated the Id2 gene via the 5 0 -upstream promoter sequence. Chromatin-immunoprecipitation revealed a direct interaction of EWS/Fli-1 with the promoter regions of the Id2, TGF-b type II receptor, cyclin D1, and c-myc genes. Since EWS/Fli-1 transactivates c-myc, a cooperative action of the chimeric protein and c-myc leads to overexpression of Id2. In the present study, we suggest that Id2 is a target of the chimeric proteins and that the c-myc/Id2 pathway plays a pivotal role in the tumorigenic processes provoked by EWS/ets proteins.
Introduction
Ewing sarcoma and peripheral primitive neuroectodermal tumor (PNET) are referred to as the Ewing sarcoma family of tumors that encompasses a group of biologically identical small round cell tumors. Ewing sarcoma is the second most common solid tumor found in the bone and soft tissue of children and young adults. Despite advances in multimodal cancer therapy, the overall long-term survival rate is still less than 60% (Paulussen et al., 2001) . Owing to the lack of unequivocal lineage markers, the histogenesis of Ewing sarcoma remains controversial. A specific chromosomal translocation, t(11;22)(q24:q12), has been reported in more than 80% of Ewing sarcomas. This chromosomal translocation results in the fusion of the 5 0 segment of the EWS gene on chromosome 22 with the 3 0 segment of the Fli-1 gene on chromosome 11 (Delattre et al., 1992) . The EWS gene also fuses with other members of the ets family, for example, ERG (Sorensen et al., 1994) , ETV1 (Jeon et al., 1995) , FEV (Peter et al., 1997) , and E1AF, which we have reported previously (Urano et al., 1996 (Urano et al., , 1998 .
Ets oncoproteins contain an 85 amino acid long domain, called the ets-domain, which has been conserved among members of the ets family. With this domain they bind as monomers to core 5 0 -GGA(A/T)-3 0 sequences, and the flanking sequences of this core determine the affinity and specificity of ets proteins to these target sequences. The functional synergy between ets oncoproteins with other transcription factors such as AP-1, Sp-1, and c-myb has been reported (Wasylyk et al., 1990; Gegonne et al., 1993; Nelsen et al., 1993; Pankov et al., 1994) . Ets family members are involved in the developmental processes of various lineages such as T cell, B cell, and neural cells. The EWS/ets chimeric proteins work as aberrant transcription factors that interfere with this legitimate development and lead to oncogenesis of Ewing sarcomas. The target genes of EWS/ets oncoproteins have extensively been investigated to understand the tumorigenic mechanism in Ewing sarcoma. EWS/Fli-1 is a strong transactivator of the c-myc promoter (Bailly et al., 1994) . Several genes such as EAT-2 (Thompson et al., 1996) , stromelysin , and fringe (May et al., 1997) are reported to be upregulated, while TGF-b type II receptor (TGFbIIR) (Im et al., 2000) , p21 (Matsumoto et al., 2001) , and p57KIP2 (Dauphinot et al., 2001) are downregulated. Furthermore, EWS/Fli-1 interacts with hsRPB7, a subunit of human RNA polymerase II (Petermann et al., 1998) , and the EWS/ Fli-1 fusion protein alters the IGF-IR signaling pathway (Toretsky et al., 1997) .
Since the ets proteins augment expression of various types of transcription factors, we presumed that there would be other genes whose expression is modified by the occurrence of the chimeric proteins. We sought for genes specifically expressed in Ewing sarcoma and found enhanced expression of the Id2 gene. Id proteins are helix-loop-helix (HLH) proteins lacking the basic amino acid domain necessary to bind DNA. Id proteins function in a dominant negative manner by sequestering ubiquitously expressed (eg, E12, E47, and E2-2) or cell-type restricted (eg, Tal-1 and MyoD) basic HLH transcription factors, thereby blocking the binding of dimerized basic HLH proteins to DNA. They regulate transcription factors that are involved in developmental processes such as myogenesis, neurogenesis, bone morphogenesis, lymphopoiesis hematopoiesis, and myeloid differentiation (Norton et al., 1998) . In transgenic chicken embryos, the ectopic expression of Id2 converts ectodermal cells to a neural crest fate (Martinsen and Bronner-Fraser, 1998) . Id2À/À mice lack lymph nodes and Peyer's patches, and show a reduced population of natural killer cells (Yokota et al., 1999) . Id proteins are also involved in cellular proliferation processes. The growth-suppressive activity of retinoblastoma proteins (RB) is reversed by Id2 through physical interactions between those proteins (Iavarone et al., 1994) . High levels of Id2 reverse the growth suppressive activity of cyclin-dependent kinase inhibitors, p16 and p21 (Lasorella et al., 1996) . Furthermore, the oncoproteins of the myc family require Id2 to bypass the regulatory function of RB (Lasorella et al., 2000) . Thus, Id2, a protein required to maintain the timing of differentiation in mammalian development, is also a potent effector in the tumorigenic process of human cancer. Here we demonstrate extremely high levels of Id2 expression in Ewing sarcomas, presumably caused by the direct interaction between EWS/ets chimeric proteins and the promoter region of the Id2 gene.
Results

Gene expression analysis with the human cDNA array
We employed a cDNA expression array system to search for candidate target genes of EWS/ets chimeric proteins. Gene expression profiles of NCR-EW2 with the EWS/Fli-1, W-ES with the EWS/ERG, and NCR-EW3 with the EWS/E1AF, and NCR-G3 embryonal carcinoma are shown in Figure 1 . Significantly high levels of c-myc and cyclin D transcripts were detected in all the cells tested. However, the levels were somewhat lower in NCR-G3 than in Ewing sarcoma cells. The highest level of Id2 transcripts was detected in Ewing sarcoma cells (Figure 1a-c) , while it was below detectable level in NCR-G3 ( Figure 1d ). As Id2 regulates cellular differentiation into various lineages, the extraordinarily high level of Id2 expression may play a crucial role in the tumorigenesis of Ewing sarcoma. Similar levels of high expression were also seen in 40S ribosomal protein S-19, heatshock 27 kD protein 1, glutathione S-transferase P, DNA-binding protein TAX and TAXREB67, RNA polymerase elongation factor SIII, guanine nucleotidebinding protein G-S, Y-box binding protein-1, proliferation-associated protein PAG, and thymosin beta-10 in all four cell lines. Why these transcripts increased still remains unclear.
Id2 expression in Ewing sarcoma
The enhanced expression of the Id2 gene was also detected by Northern blot analysis. Id2 was highly expressed in all the Ewing sarcoma cell lines, as well as in neuroblastoma cells, but was below a detectable level in NCR-G3 (Figure 2 ) and in HeLa cells (data not shown). Total RNA was also extracted from frozen blocks of tissues that had been diagnosed as Ewing sarcoma by immunohistochemistry and the detection of chimeric genes. Id2 was detected in all tissue samples from Ewing sarcoma. We further examined the expression of Id2 in comparison with other undifferentiated solid tumors in children, rhabdomyosarcoma, and neuroblastoma. Tumors are randomly selected from freeze-stock specimens. The chimeric genes in Ewing sarcoma specimens were found to be EWS/Fli-1. Significantly higher levels of Id2 transcripts were detected in Ewing sarcoma than in rhabdomyosarcoma and neuroblastoma. The high level of Id2 in Ewing sarcoma leads us to speculate that the EWS/ets gene products directly promote Id2 expression in vivo.
Activation of the Id2 promoter by the EWS/ets chimeric protein
We examined whether EWS/ets proteins activate the promoter of the Id2 gene. A DNA segment containing the cis-regulatory element of Id2, nucleotide À221 to À46, was placed in either the forward (IdL-FWD) or reverse (IdL-REV) direction upstream of the luciferase gene. The reporter gene was co-transfected with an EWS/ets expression vector and phRL-TK reference vector. The luciferase activity was significantly enhanced with EWS/Fli-1, EWS/ERG, and EWS/E1AF (Figure 3a -c). The reversely ligated promoter produced almost the same results. This result is consistent with the fact that the upstream regulatory element usually works in either direction in the transcription process. Next, we introduced point mutations into the ets consensus sequence to analyze whether this sequence is required for the promoter activity ( Figure 3d ). The promoter region contains a canonical ets consensus sequence 50-bp downstream of the E-box where basic-HLH transcription factors interact. When the guanine (À156) was replaced with thymine the enhancing effect of EWS/Fli-1 decreased by about 25% (Figure 3e ). Similar results were obtained when the adenine (À155) was replaced with cytosine. Thus, the ets consensus sequence is required to exert increased activation. When the adenine (À204) in the E-box was replaced with thymine, or thymine (À201) was replaced with cytosine, the promoter activity was significantly reduced by 80%. Similar results were obtained when EWS/E1AF was co-transfected as an effector ( Figure 3f ). Promoter activity was reduced by 30% after ets point mutation and by 70% after E-box mutation. A reporter construct IdS, lacking the E-box and juxtaposed sequences, was produced to allow analysis of the activation effect of chimeric proteins in the absence of E-box influence. Single nucleotide mutations in the ets site of the truncated promoter, at nucleotide positions À156 and À155, decreased the promoter activity by 46 and 45%, respectively ( Figure 3g ). These results imply that these two promoter elements, the E-box and the ets recognition sequence, contribute independently in the activation of the regulatory element of the Id2 gene. The reporter genes were transfected into Ewing sarcoma cell lines to investigate whether they are functional in cells with native chimeric genes. In the NCR-EW2 cell line with EWS/Fli-1, both IdL and IdS were active (Figure 4a) . The mutations at the ets site resulted in a decrease in activity by 30-40%. Similarly, in W-ES cells with EWS/ERG, the ets mutations diminished the promoter activity by 50-60% (Figure 4b ). Owing to very low transfection efficiency no transcriptional activity was detected in NCR-EW3 cells with EWS/E1AF.
Binding of EWS/ets protein to the Id2 cis-regulatory element in vivo
We then used the chromatin immunoprecipitation (ChIP) technique to examine whether EWS/ets gene products interact with the Id2 promoter region. Chromatin was extracted from formaldehyde-treated cells, and anti-Fli-1 antibody or a corresponding amount of nonimmune IgG was added. Analysis by PCR detected Figure 5 ). Neither the cis-element containing ets consensus sequences of EAT/MCL-1 nor of the matrix metalloproteinase-1 (MMP-1) was detected in either of the immunoprecipitates. Furthermore, the b-actin fragment was also undetected in either immunoprecipitate. These results indicate that the binding of the chimeric protein to the Id2 promoter region is specific. It is unlikely that the PCR products are from an intact Fli-1-chromatin complex, because Fli-1 transcripts are not detected in Ewing sarcoma cells (Bailly et al., 1994) , and a single band identical to the EWS/Fli-1 protein was detected in the immunoprecipitates from Ewing cells by the anti-Fli-1 antibody. We here demonstrate that the EWS/Fli-1 gene products interact directly with the regulatory elements of Id2, c-myc, cyclin D and TGFbIIR.
Discussion
In this study, we have demonstrated a direct transactivation of Id2 by EWS/ets chimeric proteins. Extremely high levels of Id2 gene expression were specifically observed in Ewing sarcoma cells and tumor tissues but not in embryonal carcinoma cells, rhabdomyosarcoma or neuroblastoma. We have also presented evidence suggesting that the EWS/ets proteins activate the Id2 gene through the direct interaction between the Id2 promoter and EWS/Fli-1 in vivo.
The substantial increase of Id2 by the EWS/ets chimeric proteins seemed to be functionally mediated through ets recognition sequences and E-box. Three Ebox/ets clusters and several other ets-like sequences exist in the 2-kb enhancing region of the Id2 gene. The E-box located 50-bp upstream of the ets consensus sequence is important for the Id2 promoter activity. The decrease in Id2 promoter activity caused by point mutations in the E-box suggests that E-box-binding proteins, predominantly c-myc, and ets proteins, contribute to upregulating Id2 expression. The synergism of the ets proteins with other transcription factors such 
(a) and into W-ES cells with EWS/ERG (b).
The luminescence intensity is expressed as a ratio of reporter vector to the phRL-TK reference vector, and the wild type (IdL-wild or IdS-wild) is regarded as 1.0 Experiments were repeated twice and each experiment was performed on duplicate wells Figure 5 Binding of EWS/Fli-1 to the Id2 promoter in vivo. Crosslinked chromatin was prepared from NCR-EW2 cells. Chromatin was incubated with anti-Fli-1 antibody or normal rabbit IgG, and the regulatory fragments were amplified by PCR from the immunoprecipitates. The DNA templates are as follows: Lane 2, immunoprecipitates with anti-Fli-1; Lane 3, immunoprecipitates with normal rabbit IgG; Lane 4: chromatin DNA corresponding to 0.05% of total input DNA; Lane 5: chromatin DNA from human placenta; Lane 6: distilled H 2 O as a negative control; Lane 1: molecular size markers. Molecular sizes are represented as base pair on the left of the panels
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as AP-1 (Wasylyk et al., 1990; Pankov et al., 1994) , Sp-1 (Seth et al., 1993) , and c-myb (Dudek et al., 1992) has been reported. In addition, DNA-binding motifs, that is, AP2, CEBP, GRE, E-box, CREB, AP-1, and SP-1, correlate with enhanced ets activity (Edelman et al., 2000) . As the recognition sequence of SP-1 is located only 30-bp upstream of the ets site in the Id2 promoter, it is suggested that the EWS/ets chimeric proteins may cooperate with SP-1 to enhance the transcriptional activity of Id2. The cooperative effect of ets and E-box-binding proteins with other transcriptional factors is supposed to be crucial to Id2 transactivation, which subsequently contributes to tumor progression.
The high level of Id2 expression may explain certain characteristics of Ewing sarcoma such as primitive morphological features and expression of neural molecules. Several neural antigens are detectable by immunohistochemical analysis in Ewing sarcoma. However, few muscular antigens are detected (Sugimoto et al., 1997) . Id proteins interact with ubiquitous bHLH class A proteins, such as E12 and E47, to block the formation of heterodimers of class A proteins and tissue-specific class B proteins, for example Tal-1 and MyoD (Benezra et al., 1990; Langlands et al., 1997) . The Id2 expression induced by the specific chimeric proteins thus prevents expression of muscular phenotypes in the Ewing sarcoma. However, expression of Id2 in neurogenesis and during retinoic acid-induced differentiation of neuroblastoma suggests that Id2 is not a general inhibitor of differentiation in neural cell types (Neuman et al., 1993) . The neurogenic potential of Ewing sarcoma may be explained by the gaining of tumorigenicity in the process of neurogenic lineage or by the overexpression of Id2 influencing precursor cells of other lineages toward neural crest and neurogenic fates. The primitive morphological appearance in the Ewing tumor family may be attributed to the high levels of Id2 that interfere with the activities of lineage-specific genes to commit cells to terminal differentiation as shown schematically in Figure 6 .
The high levels of Id2 may also explain the high malignancy and poor prognosis of this tumor. Id2 expression reverses the inhibition of cellular proliferation and the block in cell cycle progression because of direct interaction of Id2 with RB via disruption of heterodimerization between Rb and E2F (Lasorella et al., 1996) . The RB mutant phenotypes, that is ectopic cellular proliferation, loss of differentiation, and cell death, are reported to manifest through uncontrolled Id2 activity in mice (Lasorella et al., 2000) . The oncogenic process of Ewing sarcoma may attribute to the Id2-mediated inhibition of RB that has a tumor suppressive activity in a series of cancers.
c-myc, which functions as an oncogenic molecule and was particularly abundant as shown by the arrays of this study, is directly induced by EWS/ets chimeric oncoproteins (Bailly et al., 1994; Noguera et al., 1992) . Id2 expression is transactivated by N-myc and c-myc through direct binding to the Id2 promoter. Id2 is overexpressed in cells carrying extra copies of the N-myc gene in neuroblastoma and mediates signaling by myc proteins (Benezra et al., 1990) . Thus, the induction of the Id2 gene seems to be augmented by myc oncoproteins that are upregulated by the EWS/ets chimeric proteins. Although further analyses are required, many essential molecules are involved in tumorigenic process executed by Id2 expression.
Based on the present experiments, we propose a possible role of EWS/ets chimeric proteins in oncogenesis of Ewing sarcoma (Figure 6 ). The chimeric proteins directly activate the Id2 gene. Moreover, they induce cmyc expression, with the subsequent high levels of c-myc further augmenting expression of Id2. Consequently, the high levels of Id2 interfere with the growth-suppressive activity of the RB protein family and the differentiation regulated by bHLH transcription factors.
Materials and methods
Cell lines and surgical samples
Surgical samples were obtained from patients with Ewing sarcoma. The cell lines used in this work and the specific fusion transcripts are shown in Table 1 . Cells were cultured in RPMI medium supplemented with 10% fetal bovine serum. The surgically resected tumor was immediately frozen in OCTcompound (Miles Inc. Diagnostic Division, Elkhart, IN, USA) for immunohistochemical procedures and for RNA extraction. Diagnosis of Ewing sarcoma was immunohistochemically defined with an anti-p30/32 MIC2 antibody, and detection of chimeric genes (EWS/Fli-1, EWS/ERG, or EWS/E1AF) was performed by a PCR technique using a specific set of primers described previously (Urano et al., 1998) . Neuroblastoma and rhabdomyosarcoma were diagnosed by immunohistological examination. The tumor specimens used in this work, and the specific fusion transcripts of Ewing sarcoma are shown in Figure 6 Possible function of EWS/ets chimeric proteins in tumorigenesis. EWS/ets fusion proteins activate the Id2 gene directly, and also indirectly as a result of activating c-myc gene. The higher levels of Id2 protein enhance cell cycle progression by inactivating RB protein family. Id2 protein, furthermore, interferes ubiquitous bHLH class A proteins to form heterodimers with tissue-specific class B proteins, and subsequently inhibits precursor cells to differentiate into a certain lineage Upregulation of Id2 by EWS/ets proteins M Fukuma et al Table 2 . This work was sanctioned by the Ethics Committee in the Keio University School of Medicine (#13-12).
Gene expression
Isolation of total RNA from Ewing sarcoma cells and tissues was performed using ISOGEN (Nippon Gene Co., Ltd, Tokyo, Japan), and the polyA + RNA was purified using OligotexTM-dT30 (JSR Corporation, Tokyo, Japan). For investigating differential gene expression, Atlas cDNA Expression Arrays (#7740-1, CLONTECH Laboratories, Inc., CA, USA) were employed. Atlas Arrays were reused three times at most to maintain a high reliability of quantitative analysis. 32 P-labeled cDNA probes were generated from each polyA + RNA sample and hybridized to the Array according to the manufacturer's instructions. The membranes were exposed on an imaging plate and the accumulated radioactivity of each spot was counted with a Bio Imaging Analyzer (BAS-III, Fuji Photo Film Co., Ltd, Tokyo, Japan). The values were normalized by the housekeeping genes spotted on the same membrane. The membrane was also exposed to a Kodak BioMax Ms X-ray film for 1-7 days to obtain a gene expression profile. For Northern blot analysis, 10 mg of each total RNA sample was analyzed as described by Thomas (1980) .
Luciferase reporter assay
The activation of the Id2 promoter was examined with a Dual Luciferase Promoter Assay System (Promega, Co., WI, USA). The promoter region was amplified by PCR with the sense and antisense primers, 5 0 -CCGCACTTACTGTACTGTACTC-3 0 and 5 0 -TGCTGAGCTAGCTGCGCTT-3 0 , respectively. The PCR product was enzymatically digested with Rsa I and Hae III, and the 176-bp band from the position À46 to À221 relative to the start site of transcription was ligated into the pGL3-promoter vector. Point mutations were introduced into the promoter sequences of Id2 ligated to the luciferase reporter gene using the Gene Editor in vitro Site-Directed Mutagenesis System (Promega). Adenosine at the position À204 relative to Upregulation of Id2 by EWS/ets proteins M Fukuma et al the transcription start site was replaced with thymine (À204A:T), or thymine at À201 was replaced with cytosine (À201T:C) to disrupt the E-box. The guanine at À156 was replaced with thymine (À156G:T), or the adenine at À155 was replaced with cytosine (À155A:C) to disrupt the ets recognition sequence. The sequence of the promoter was confirmed by DNA sequence analysis (MegaBACE 1000, Amersham Pharmacia Biotech, CA, USA). An EWS/Fli-1 expression vector (Type II: EWS exon 7/Fli-l exon 5) was constructed as follows. A 1771-bp cDNA product was amplified from the NCR-EW2 cell line using PCR primers, sense: 5 0 -GGAAGGAGA-GAAAATGGCGTCC-3 0 and antisense: 5 0 -CTCACAA-GATGCTAGGAGACTGAG-3 0 , and ligated into the pGEM-T-Easy vector. The 1.8-kb fragment from the Not I digests of this first vector construct was ligated into the Not I site of the expression vector pcDNA3 (Promega). After confirmation of incorporation of the cDNA construct by DNA sequencing, expression was analyzed in HeLa cells by Western blotting. An expression vector of the fusion protein, EWS/Fli-1, EWS/ERG (Ohno et al., 1994) or EWS/E1AF (Urano et al., 1996 (Urano et al., , 1998 was cotransfected with the luciferase-reporter vector into HeLa cells using Lipofectin Reagent (Life Technologies, MD, USA). The cells were also transfected together with TK-RL reference vector for the standardization of transfection efficiency. The cells were treated according to the directions of the manufacturer. The intensity of the luminescence was measured by a luminometer, GENE LIGHT 55 (Microtec Co., Ltd., Chiba, Japan), and expressed in the ratio of the first luminescence from the reporter gene to the second luminescence from the RL-TK reference gene.
Chromatin immunoprecipitation
The chromatin DNA that interacts with EWS/Fli-1 was detected according to the procedure as described (Moreno et al., 1999) with minor modifications. Briefly, cells fixed with 1% formaldehyde were dispersed in cell lysis buffer [10 mM HEPES pH 7.5, 10 mM EDTA, 0.5 mM EGTA, 0.5% IGEPAL CA-330 (Sigma, St Louis, MO, USA), and Protease Inhibitor Cocktail (Roche Diagnostics GmbH, Mannheim, Germany)]. Nuclei were pelleted, lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% IGEPAL, 0.1% sodium dodecylsulfate, 0.5% deoxycholate, and Protease Inhibitor Cocktail), sonicated and centrifuged. The supernatant was used as chromatin solution. Anti-Fli-1 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or the equivalent amount of rabbit IgG was added and Dynabeads Protein G (Dynal ASA, Oslo, Norway) was employed to precipitate the antigen. The pairs of sense and antisense primers for PCR used to detect the promoter regions were as follows, c-myc: 
